ELOX
Eloxx Pharmaceuticals, Inc.
13.90$
+1.1%
vs. previous close
Closing price · As of: Oct 12, 2026
Statements
Cash Flow
Eloxx Pharmaceuticals, Inc. (ELOX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -4.8 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 15 | Q3 16 | Q4 16 | Q1 17 | Q3 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q1 25 | Q2 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.1 | -0.6 | -0.4 | -0.4 | -0.5 | -5.7 | -8.5 | -8.1 | -9.1 | -9.2 | -9.6 | -11 | -9.3 | -12 | -6.3 | -5.3 | -4.7 | -7.7 | -9.8 | -7.6 | -9.9 | -9.5 | -9.7 | -6.9 | -6.8 | -2.1 | -3.5 | 1.2 | -1.8 | -5.5 | -4.8 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.1 | |
| 0.0 | 0.2 | 0.1 | -0.1 | 0.0 | 2.1 | -1.3 | 0.3 | 1.1 | -0.2 | 1.6 | -1.6 | -0.6 | -2.2 | -0.7 | -0.3 | -0.1 | -0.6 | -1.0 | 0.2 | 0.2 | 0.6 | 0.0 | -0.4 | -1.9 | 1.4 | -0.3 | 2.6 | 0.0 | -1.7 | -0.1 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| – | 0.1 | – | 0.0 | – | -0.1 | 0.0 | 0.0 | -0.2 | 0.0 | -27 | -16 | 9.1 | 16 | 11 | 6.8 | – | – | 2.1 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.9 | 1.9 | 0.0 | 0.0 | |
| 1.2 | – | 0.3 | 0.5 | 0.3 | – | 54 | 0.0 | 2.5 | 5.2 | 41 | -0.1 | 0.5 | -0.5 | -0.5 | -1.2 | -1.3 | 1.3 | 46 | 3.4 | -0.2 | 7.0 | – | 1.5 | -7.5 | 1.4 | 3.7 | -0.9 | 1.9 | 7.0 | 60 | |
| 3.4 | -0.5 | -0.1 | 0.1 | -0.2 | 18 | 45 | -8.1 | -6.7 | -4.0 | 4.8 | -27 | 0.3 | 3.4 | 4.5 | 0.2 | -5.9 | -6.4 | 39 | -4.3 | -10 | -2.5 | -9.8 | -5.5 | -14 | -0.6 | 0.5 | 0.3 | 0.1 | 1.4 | 56 | |
| -1.1 | -0.6 | -0.4 | -0.4 | -0.5 | -5.8 | -8.6 | -8.1 | -9.2 | -9.2 | -9.6 | -11 | -9.3 | -12 | -6.3 | -5.3 | -4.7 | -7.7 | -9.8 | -7.7 | -10.0 | -9.5 | -9.8 | -7.0 | -6.8 | -2.1 | -3.5 | 1.2 | -1.8 | -5.5 | -4.8 |
Data as of: October 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.